Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H23N3O |
Molecular Weight | 309.4054 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCCOC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3
InChI
InChIKey=CNBGNNVCVSKAQZ-UHFFFAOYSA-N
InChI=1S/C19H23N3O/c1-21(2)13-8-14-23-19-17-11-6-7-12-18(17)22(20-19)15-16-9-4-3-5-10-16/h3-7,9-12H,8,13-15H2,1-2H3
Molecular Formula | C19H23N3O |
Molecular Weight | 309.4054 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68001591
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68001591
Benzydamine (benzydamine hydrochloride, PHARIXIA®) is a benzyl-indazole having analgesic, antipyretic, and anti-inflammatory effects. It is indicated for the relief of pain in acute sore throat and for the symptomatic relief of oro-pharyngeal mucositis caused by radiation therapy.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0002539 Sources: https://www.ncbi.nlm.nih.gov/pubmed/4044146 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PHARIXIA Approved UsePHARIXIA (benzydamine hydrochloride) is indicated for the relief of pain in acute sore throat and for the symptomatic relief of oro-pharyngeal mucositis caused by radiation therapy. |
|||
Primary | PHARIXIA Approved UsePHARIXIA (benzydamine hydrochloride) is indicated for the relief of pain in acute sore throat and for the symptomatic relief of oro-pharyngeal mucositis caused by radiation therapy. |
PubMed
Title | Date | PubMed |
---|---|---|
Several therapies may prevent or reduce the severity of oral mucositis associated with cancer treatment. | 2006 |
|
Benzydamine N-oxygenation as a measure of flavin-containing monooxygenase activity. | 2006 |
|
Interventions for preventing oral mucositis for patients with cancer receiving treatment. | 2006 Apr 19 |
|
Local irritant effects of topical oral sprays on oral mucosa in mice. | 2006 Jan-Feb |
|
Oral mucositis. | 2006 May |
|
An evaluation of the efficacy of aspirin and benzydamine hydrochloride gargle for attenuating postoperative sore throat: a prospective, randomized, single-blind study. | 2006 Oct |
|
Cancer treatment-induced mucositis pain: strategies for assessment and management. | 2006 Sep |
|
A pilot study of chlorhexidine and benzydamine oral rinses for the prevention and treatment of irradiation mucositis in patients with head and neck cancer. | 2006 Sep-Oct |
|
[Clinical experience with tantum rosa (benzydamine hydrochloride) in prophylaxis and treatment of vaginitis and proctitis, following radiotherapy of patients with cancer of the vagina and uterus]. | 2007 |
|
Recreational abuse with benzydamine hydrochloride (tantum rosa). | 2007 |
|
Cytotoxicity of mouthrinses on epithelial cells by micronucleus test. | 2007 Apr |
|
Digital analysis of mouthrinses' staining characteristics on provisional acrylic resins. | 2007 Apr |
|
Interventions for treating oral mucositis for patients with cancer receiving treatment. | 2007 Apr 18 |
|
Mucocutaneous lesions of Behcet's disease. | 2007 Aug 31 |
|
Effect of leukocyte inhibitors benzydamine and cyclophosphamide, on lung injury caused by Tityus discrepans scorpion venom. | 2007 Dec 15 |
|
Dexpanthenol pastille and benzydamine hydrochloride spray for the prevention of post-operative sore throat. | 2007 Feb |
|
Combined photocontact dermatitis to benzydamine hydrochloride and the emulsifiers, Span 60 and Tween 60 contained in Tantum cream. | 2007 Jul |
|
Reduction of mouth malodour and volatile sulphur compounds in intensive care patients using an essential oil mouthwash. | 2007 Jul |
|
Novel hydrogels via click chemistry: synthesis and potential biomedical applications. | 2007 Jun |
|
Effect of genetic variants of the human flavin-containing monooxygenase 3 on N- and S-oxygenation activities. | 2007 Mar |
|
Cancer treatment-induced oral mucositis. | 2007 Mar-Apr |
|
Interventions for preventing oral mucositis for patients with cancer receiving treatment. | 2007 Oct 17 |
|
New pathways for alimentary mucositis. | 2008 |
|
Antifungal effect of mouth rinses on oral Candida counts and salivary flow in treatment-naïve HIV-infected patients. | 2008 Aug |
|
Altered metabolism of growth hormone receptor mutant mice: a combined NMR metabonomics and microarray study. | 2008 Jul 23 |
|
Effect of different mouth rinses on third molar surgery-related oral malodor. | 2008 Mar |
|
Spectrophotometric determination of benzydamine HCl, levamisole HCl and mebeverine HCl through ion-pair complex formation with methyl orange. | 2008 Mar |
|
Burning mouth syndrome. | 2008 Mar 14 |
|
[Medicine consumption and the internet: critical evaluation of a virtual community]. | 2008 May-Jun |
|
Evaluation of sutures after immersion in nonalcoholic benzydamine hydrochloride mouthrinse by scanning electron microscopy. | 2008 Sep |
|
Benzydamine hydrochloride buccal bioadhesive gels designed for oral ulcers: preparation, rheological, textural, mucoadhesive and release properties. | 2009 |
|
[Misuse of substances theoretically without abuse potential--case series]. | 2009 |
|
Inter-individual variation in flavin-containing monooxygenase 3 in livers from Japanese: correlation with hepatic transcription factors. | 2009 |
|
Stevens-Johnson Syndrome triggered by chemical hair relaxer: a case report. | 2009 Aug 5 |
|
Ingestions of benzydamine-containing vaginal preparations. | 2009 Feb |
|
Relief of radiation-induced oral mucositis in head and neck cancer. | 2009 Jan-Feb |
|
Formulation studies of benzydamine mucoadhesive formulations for vaginal administration. | 2009 Jul |
|
Photopatch testing with an extended series of photoallergens: a 5-year study. | 2009 Jun |
|
Benzydamine for prophylaxis of radiation-induced oral mucositis in head and neck cancers: a double-blind placebo-controlled randomized clinical trial. | 2009 Mar |
|
Expression and characterization of functional dog flavin-containing monooxygenase 3. | 2009 Oct |
|
Recreational use of benzydamine as a hallucinogen among street youth in Brazil. | 2009 Sep |
|
Lymphomatoid photocontact dermatitis to benzydamine hydrochloride. | 2010 Feb |
|
Thermally sensitive gels based on chitosan derivatives for the treatment of oral mucositis. | 2010 Feb |
|
Respiratory symptoms and inflammatory responses to Difflam throat-spray intervention in half-marathon runners: a randomised controlled trial. | 2010 Feb |
|
Oral rinses, mouthwashes and sprays for improving recovery following tonsillectomy. | 2010 Jan 20 |
|
Direct electrochemistry of drug metabolizing human flavin-containing monooxygenase: electrochemical turnover of benzydamine and tamoxifen. | 2010 Jan 20 |
|
Hippocampal and caudate volume reductions in antipsychotic-naive first-episode schizophrenia. | 2010 Mar |
|
[Use abusive of benzydamine in Brazil: an overview in pharmacovigilance]. | 2010 May |
|
Effect on postoperative sore throat of spraying the endotracheal tube cuff with benzydamine hydrochloride, 10% lidocaine, and 2% lidocaine. | 2010 Oct |
|
The development and in vitro evaluation of sustained release tablet formulations of benzydamine hydrochloride and its determination. | 2010 Sep |
Sample Use Guides
Not less than 15 mL of the liquid should be used for each gargle or rinse and repeated three or four times a day, depending on the severity of the treated condition. The liquid should be kept in contact with the inflamed mucosa for at least 30 seconds and then expelled from the mouth. Administration should begin the day prior to commencement of radiation therapy and continue daily during the treatment period as well as after cessation of radiation applications until desired improvement is obtained.
In acute sore throat, gargle with 15 mL every 1.5 to 3 hours. The solution should be expelled from the mouth after use.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10207535
Benzydamine significantly reduced the basal production of both prostaglandin E2 (PGE2) and 6-keto-PGF1 alpha, the stable breakdown product of prostaglandin I2 (PGI2), in unstimulated human gingival fibroblasts. When the cells were treated simultaneously with benzydamine and the cytokines IL-1beta or TNF-alpha, the agent benzydamine reduced (P < 0.05) the stimulatory effect of IL-1beta and TNF-alpha respectively, on PGE2 and PGI2 production in human gingival fibroblasts. Furthermore, benzydamine reduced (P < 0.05) both the basal level and the cytokine-induced 3H-arachidonic acid release in gingival fibroblasts. The addition of exogenous arachidonic acid to the cells resulted in enhanced PGE2 production, which was reduced (P < 0.05) in the presence of benzydamine.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:13:41 UTC 2023
by
admin
on
Fri Dec 15 15:13:41 UTC 2023
|
Record UNII |
4O21U048EF
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QG02CC03
Created by
admin on Fri Dec 15 15:13:41 UTC 2023 , Edited by admin on Fri Dec 15 15:13:41 UTC 2023
|
||
|
WHO-VATC |
QM02AA05
Created by
admin on Fri Dec 15 15:13:41 UTC 2023 , Edited by admin on Fri Dec 15 15:13:41 UTC 2023
|
||
|
WHO-ATC |
M02AA05
Created by
admin on Fri Dec 15 15:13:41 UTC 2023 , Edited by admin on Fri Dec 15 15:13:41 UTC 2023
|
||
|
WHO-ATC |
R02AX03
Created by
admin on Fri Dec 15 15:13:41 UTC 2023 , Edited by admin on Fri Dec 15 15:13:41 UTC 2023
|
||
|
WHO-VATC |
QM01AX07
Created by
admin on Fri Dec 15 15:13:41 UTC 2023 , Edited by admin on Fri Dec 15 15:13:41 UTC 2023
|
||
|
WHO-ATC |
G02CC03
Created by
admin on Fri Dec 15 15:13:41 UTC 2023 , Edited by admin on Fri Dec 15 15:13:41 UTC 2023
|
||
|
WHO-ATC |
A01AD02
Created by
admin on Fri Dec 15 15:13:41 UTC 2023 , Edited by admin on Fri Dec 15 15:13:41 UTC 2023
|
||
|
WHO-VATC |
QA01AD02
Created by
admin on Fri Dec 15 15:13:41 UTC 2023 , Edited by admin on Fri Dec 15 15:13:41 UTC 2023
|
||
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 15:13:41 UTC 2023 , Edited by admin on Fri Dec 15 15:13:41 UTC 2023
|
||
|
WHO-ATC |
M01AX07
Created by
admin on Fri Dec 15 15:13:41 UTC 2023 , Edited by admin on Fri Dec 15 15:13:41 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1927
Created by
admin on Fri Dec 15 15:13:41 UTC 2023 , Edited by admin on Fri Dec 15 15:13:41 UTC 2023
|
PRIMARY | |||
|
100000086414
Created by
admin on Fri Dec 15 15:13:41 UTC 2023 , Edited by admin on Fri Dec 15 15:13:41 UTC 2023
|
PRIMARY | |||
|
DTXSID7047859
Created by
admin on Fri Dec 15 15:13:41 UTC 2023 , Edited by admin on Fri Dec 15 15:13:41 UTC 2023
|
PRIMARY | |||
|
3881
Created by
admin on Fri Dec 15 15:13:41 UTC 2023 , Edited by admin on Fri Dec 15 15:13:41 UTC 2023
|
PRIMARY | |||
|
m2395
Created by
admin on Fri Dec 15 15:13:41 UTC 2023 , Edited by admin on Fri Dec 15 15:13:41 UTC 2023
|
PRIMARY | Merck Index | ||
|
1425
Created by
admin on Fri Dec 15 15:13:41 UTC 2023 , Edited by admin on Fri Dec 15 15:13:41 UTC 2023
|
PRIMARY | RxNorm | ||
|
D001591
Created by
admin on Fri Dec 15 15:13:41 UTC 2023 , Edited by admin on Fri Dec 15 15:13:41 UTC 2023
|
PRIMARY | |||
|
4O21U048EF
Created by
admin on Fri Dec 15 15:13:41 UTC 2023 , Edited by admin on Fri Dec 15 15:13:41 UTC 2023
|
PRIMARY | |||
|
DB09084
Created by
admin on Fri Dec 15 15:13:41 UTC 2023 , Edited by admin on Fri Dec 15 15:13:41 UTC 2023
|
PRIMARY | |||
|
Benzydamine
Created by
admin on Fri Dec 15 15:13:41 UTC 2023 , Edited by admin on Fri Dec 15 15:13:41 UTC 2023
|
PRIMARY | |||
|
211-388-8
Created by
admin on Fri Dec 15 15:13:41 UTC 2023 , Edited by admin on Fri Dec 15 15:13:41 UTC 2023
|
PRIMARY | |||
|
CHEMBL12610
Created by
admin on Fri Dec 15 15:13:41 UTC 2023 , Edited by admin on Fri Dec 15 15:13:41 UTC 2023
|
PRIMARY | |||
|
12555
Created by
admin on Fri Dec 15 15:13:41 UTC 2023 , Edited by admin on Fri Dec 15 15:13:41 UTC 2023
|
PRIMARY | |||
|
SUB05770MIG
Created by
admin on Fri Dec 15 15:13:41 UTC 2023 , Edited by admin on Fri Dec 15 15:13:41 UTC 2023
|
PRIMARY | |||
|
642-72-8
Created by
admin on Fri Dec 15 15:13:41 UTC 2023 , Edited by admin on Fri Dec 15 15:13:41 UTC 2023
|
PRIMARY | |||
|
134500
Created by
admin on Fri Dec 15 15:13:41 UTC 2023 , Edited by admin on Fri Dec 15 15:13:41 UTC 2023
|
PRIMARY | |||
|
94563
Created by
admin on Fri Dec 15 15:13:41 UTC 2023 , Edited by admin on Fri Dec 15 15:13:41 UTC 2023
|
PRIMARY | |||
|
C83548
Created by
admin on Fri Dec 15 15:13:41 UTC 2023 , Edited by admin on Fri Dec 15 15:13:41 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |